Dapawin
Generic Name
Dapagliflozin
Manufacturer
Acme Pharmaceuticals Ltd.
Country
Bangladesh
Loading images...
Price Details
Current market pricing information
| Variant | Unit Price | Strip Price |
|---|---|---|
| dapawin 5 mg tablet | ৳ 16.00 | ৳ 160.00 |
Description
Overview of the medicine
Dapagliflozin is an SGLT2 inhibitor used for the treatment of type 2 diabetes mellitus, heart failure (HFrEF and HFpEF), and chronic kidney disease.
Uses & Indications
Dosage
Adults
The recommended starting dose is 5 mg orally once daily. May be increased to 10 mg once daily based on efficacy and tolerability.
Elderly
No dose adjustment is required based on age alone. However, renal function should be monitored.
Renal_impairment
No dose adjustment needed for eGFR ≥45 mL/min/1.73 m². Initiation not recommended for eGFR <25 mL/min/1.73 m².
How to Take
Take orally once daily in the morning, with or without food.
Mechanism of Action
Dapagliflozin selectively inhibits the sodium-glucose co-transporter 2 (SGLT2) in the renal proximal tubules, reducing glucose reabsorption and increasing urinary glucose excretion, thereby lowering blood glucose levels.
Pharmacokinetics
Onset
Glucose-lowering effect typically begins within hours of administration.
Excretion
Approximately 75% of the dose is excreted in the urine and 21% in the feces.
Half life
The mean terminal half-life is approximately 12.9 hours in healthy subjects.
Absorption
Rapidly absorbed after oral administration, with peak plasma concentration (Cmax) achieved within approximately 2 hours.
Metabolism
Primarily metabolized via O-glucuronidation by UGT1A9 to inactive metabolites.
Side Effects
Contraindications
- History of serious hypersensitivity reaction to dapagliflozin
- Patients with severe renal impairment, end-stage renal disease (ESRD), or on dialysis.
Drug Interactions
Lithium
Dapagliflozin may decrease serum lithium concentrations.
Diuretics
May increase the risk of dehydration and hypotension.
Insulin and Insulin Secretagogues (e.g., Sulfonylureas)
Increased risk of hypoglycemia; a lower dose of insulin or secretagogue may be required.
Storage
Store below 30°C in a dry place, protected from light and moisture. Keep out of reach of children.
Overdose
In case of overdose, initiate appropriate supportive treatment. Dapagliflozin is unlikely to be removed by dialysis.
Pregnancy & Lactation
Not recommended during pregnancy (Pregnancy Category C/D in some guidelines) and lactation due to potential adverse effects on kidney development.
Side Effects
Contraindications
- History of serious hypersensitivity reaction to dapagliflozin
- Patients with severe renal impairment, end-stage renal disease (ESRD), or on dialysis.
Drug Interactions
Lithium
Dapagliflozin may decrease serum lithium concentrations.
Diuretics
May increase the risk of dehydration and hypotension.
Insulin and Insulin Secretagogues (e.g., Sulfonylureas)
Increased risk of hypoglycemia; a lower dose of insulin or secretagogue may be required.
Storage
Store below 30°C in a dry place, protected from light and moisture. Keep out of reach of children.
Overdose
In case of overdose, initiate appropriate supportive treatment. Dapagliflozin is unlikely to be removed by dialysis.
Pregnancy & Lactation
Not recommended during pregnancy (Pregnancy Category C/D in some guidelines) and lactation due to potential adverse effects on kidney development.
Frequently Asked Questions
Common questions about this medicine
Pack Sizes
Shelf Life
24 months from the date of manufacture.
Availability
Pharmacies, hospitals
Approval Status
Approved by FDA and DGDA
Patent Status
Patent expired in some regions, generic versions available
Clinical Trials
Dapagliflozin has been evaluated in extensive clinical trials (e.g., DECLARE-TIMI 58, DAPA-HF, DAPA-CKD) demonstrating its efficacy and safety, including cardiovascular and renal benefits.
Lab Monitoring
- Renal function (eGFR) should be assessed before initiation and monitored periodically during treatment.
- Glycemic control (HbA1c, FBG) should be regularly monitored.
- Electrolyte levels may be monitored if there is a risk of volume depletion.
Doctor Notes
- Educate patients on the importance of hydration and good hygiene to mitigate the risk of infections.
- Monitor renal function (eGFR) regularly, especially in elderly patients or those with pre-existing kidney conditions.
- Counsel patients on the signs and symptoms of DKA and Fournier's gangrene and instruct them to seek urgent medical attention if these occur.
Patient Guidelines
- Stay well-hydrated, especially during illness or in hot weather.
- Practice good personal hygiene to reduce the risk of genital and urinary tract infections.
- Report any symptoms of DKA (e.g., nausea, vomiting, abdominal pain, rapid breathing) or Fournier's gangrene (e.g., pain, tenderness, swelling in the genital or perineal area).
Missed Dose Advice
If a dose is missed, take it as soon as remembered on the same day. Do not take two doses on the same day.
Driving Precautions
Dapagliflozin generally has no or negligible influence on the ability to drive or use machines. However, patients should be cautious about hypoglycemia, especially if used in combination with insulin or sulfonylureas.
Lifestyle Advice
- Maintain a healthy diet and engage in regular physical activity as advised by your doctor.
- Diabetic patients should ensure proper foot care.
Alternative Medicines in Bangladesh
Similar medicines available in the market
Global Brand Names
International brand names for this medicine. Click a brand to search for detailed information.